Article Information
History
- December 12, 2017.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Francisco Javier García-Rodríguez1,2,
- Carmen Martínez-Fernández1,
- David Brena1,
- Ernest Nadal3,
- Mike Boxem4,
- Sebastian Honnen5,
- Antonio Miranda-Vizuete*,6,
- Alberto Villanueva*,2 and
- Julián Cerón1,*
- 1Modeling human diseases in C. elegans. Genes, Diseases and Therapies Program, Bellvitge Biomedical Research Institute - IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
- 2Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L’Hospitalet del Llobregat, Barcelona, Spain
- 3Thoracic Oncology Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L’Hospitalet de Llobregat, Barcelona, Spain
- 4Division of Developmental Biology, Department of Biology, Faculty of Science, Utrecht University, 3584 CH, Utrecht, The Netherlands
- 5Heinrich Heine University Düsseldorf, Medical Faculty, Institute of Toxicology, D-40225 Düsseldorf, Germany
- 6Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, E-41013 Sevilla, Spain
- ↵*Authors for correspondence
Posted December 12, 2017.
Genetic and cellular sensitivity of Caenorhabditis elegans to the chemotherapeutic agent cisplatin
